Severe combined immunodeficiency: Difference between revisions

From IDWiki
(Created page with "== Background == === Epidemiology === * Most common form of severe primary immunodeficiency === Pathophysiology === * No or almost no T-cells, and any that exist do not work...")
 
(added management section)
Line 16: Line 16:
== Diagnosis ==
== Diagnosis ==
* Usually diagnosed at birth with newborn screen containing a TREC (T-cell receptor excision circles) assay
* Usually diagnosed at birth with newborn screen containing a TREC (T-cell receptor excision circles) assay

== Management ==
* Initially treated supportively with management of infections and replacement of immunoglomubins
* Protective isolation in hospital with positive pressure rooms
* Antibiotic and antifungal prophylaxis to reduce frequency and severity of infections
** Commonly-used antibiotics include [[sulfisoxazole]], [[amoxicillin]], [[trimethoprim-sulfamethoxazole]], or [[azithromycin]]
* Avoid live-attenuated vaccines, but can continue to give killed or subunit vaccines (though they may not mount much response)
* Definitive treatment is [[hematopoietic stem cell transplantation]], ideally from HLA-identical sibling
* Gene therapy is an area of active research


== Prognosis ==
== Prognosis ==

Revision as of 13:54, 10 May 2020

Background

Epidemiology

  • Most common form of severe primary immunodeficiency

Pathophysiology

  • No or almost no T-cells, and any that exist do not work properly
  • Many genetic abnormalities can lead to this condition, and may cause related defects in B and NK cell lines
  • However, given that T-cells are required for B-cell function, all SCID patients are functionally B-cell deficient

Definition

  • T-cell count <300 cells/μL and no T-cell response to mitogens (<10% compared to controls)
  • Hypomorphic SCID is less severe, with a normal number of T-cells, but with T-cell function <30% compare to controls

Clinical Presentation

Diagnosis

  • Usually diagnosed at birth with newborn screen containing a TREC (T-cell receptor excision circles) assay

Management

  • Initially treated supportively with management of infections and replacement of immunoglomubins
  • Protective isolation in hospital with positive pressure rooms
  • Antibiotic and antifungal prophylaxis to reduce frequency and severity of infections
  • Avoid live-attenuated vaccines, but can continue to give killed or subunit vaccines (though they may not mount much response)
  • Definitive treatment is hematopoietic stem cell transplantation, ideally from HLA-identical sibling
  • Gene therapy is an area of active research

Prognosis

  • Uniformly fatal in childhood unless treated